Key Laboratory of Birth Defects and Related Diseases of Women and Children, West China Second University Hospital, Ministry of Education, Sichuan University, Chengdu, China.
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
BMC Pediatr. 2024 Aug 10;24(1):517. doi: 10.1186/s12887-024-04991-w.
BCR::ABL1-like or Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) was first reported in 2009. Ph-like ALL is characterized by gene signature similar to Philadelphia chromosome ALL, but without BCR::ABL1 fusions. Molecularly, Ph-like ALL is divided into seven categories, with CRLF2 and ABL-class rearrangements being the two most common subtypes, exhibiting alterations in distinct downstream signaling cascades.
We report a rare case of pediatric Ph-like ALL with concomitant CRLF2 and ABL1 rearrangements. CRLF2 was fused with P2RY8, its most common fusion partner, whereas ABL1 was fused with MYO18B, a novel fusion partner that has not been previously reported. The 4-year-old female patient was treated using the national multicenter CCCG-ALL-2020 protocol with the addition of dasatinib at the end of induction when ABL1 rearrangement was confirmed by RNA-seq. Morphologically and molecularly, the patient remained in continuous remission until the last follow-up. To the best of our knowledge, this is the first case of Ph-like ALL harboring two distinct rearrangement categories.
Our results identified that ABL1 rearrangement and CRLF2 rearrangement can coexist. The application of FISH, whole transcription sequencing, PCR can help us to have a more comprehensive understanding of ALL cytogenetics and molecular biology. Further studies are needed to explore the role of targeted therapies in such rare clinical scenarios.
BCR::ABL1 样或费城染色体样(Ph 样)急性淋巴细胞白血病(ALL)于 2009 年首次报道。Ph 样 ALL 的特征是基因特征类似于费城染色体 ALL,但没有 BCR::ABL1 融合。从分子角度来看,Ph 样 ALL 分为七类,CRLF2 和 ABL 类重排是最常见的两种亚型,表现出不同下游信号级联的改变。
我们报告了一例罕见的伴有 CRLF2 和 ABL1 重排的儿童 Ph 样 ALL。CRLF2 与最常见的融合伙伴 P2RY8 融合,而 ABL1 与 MYO18B 融合,后者是一种以前未报道过的新型融合伙伴。这位 4 岁的女性患者按照国家多中心 CCCG-ALL-2020 方案治疗,并在诱导结束时通过 RNA-seq 确认 ABL1 重排后加用达沙替尼。从形态学和分子学上看,该患者一直处于持续缓解状态,直至最后一次随访。据我们所知,这是首例同时存在两种不同重排类型的 Ph 样 ALL。
我们的结果表明 ABL1 重排和 CRLF2 重排可以共存。应用 FISH、全转录测序、PCR 可以帮助我们更全面地了解 ALL 细胞遗传学和分子生物学。需要进一步研究来探索此类罕见临床情况下靶向治疗的作用。